Apr 11, 2022 / 07:00PM GMT
Ami Fadia - Needham & Company, LLC - Analyst
Good afternoon, everyone. Welcome again to the next session with Cognition Therapeutics. I'm Ami Fadia; I cover neuroscience and targeted oncology here at Needham. And it's my pleasure to be hosting Lisa Ricciardi, who's the CEO of the company; as well as Jim O'Brien, who is the Chief Financial Officer. Lisa will be taking you through a presentation. (Conference Instructions)
With that, Lisa, please go ahead.
Lisa Ricciardi - Cognition Therapeutics, Inc. - CEO
Thank you, Ami. A pleasure to be here. Thank you for including us at Needham's panel this afternoon. I was so eager to get to the forward-looking statement, now I'm struggling to get back to it. So here you have it. We completed our IPO in October and are delighted to have raised the money we need for our trials.
Brief background on our company. Neurodegenerative disorders, age-related neurodegenerative disorders, and specifically, the central nervous system as well as the retina, which in shorthand means Alzheimer's disease, dementia with
Cognition Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers